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Background: There is widespread concern that treatment with biologic agents may be associated with suboptimal postoperative outcome after 
surgery for inflammatory bowel diseases (IBD).
Aim: We aimed to search and analyze the literature regarding the potential association of biologic treatment on adverse postoperative outcome 
in patients with IBD. We used the subject as a case in point for surgical research. The aim was not to conduct a new systematic review.
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Method: This is an updated narrative review written in a collaborative method by authors invited through Twitter via the following hashtags 
(#OpenSourceResearch and #SoMe4Surgery). The manuscript was presented as slides on Twitter to allow discussion of each section of the paper 
sequentially. A Google document was created, which was shared across social media, and comments and edits were verified by the primary author 
to ensure accuracy and consistency.
Results: Forty-one collaborators responded to the invitation, and a total of 106 studies were identified that investigated the potential association 
of preoperative biological treatment on postoperative outcome in patients with IBD. Most of these studies were retrospective observational co-
horts: 3 were prospective, 4 experimental, and 3 population-based studies. These studies were previously analyzed in 10 systematic/narrative reviews 
and 14 meta-analyses. Type of biologic agents, dose, drug concentration, antidrug antibodies, interval between last dose, and types of surgery 
varied widely among the studies. Adjustment for confounders and bias control ranged from good to very poor. Only 10 studies reported postoper-
ative outcome according to Clavien–Dindo classification.
Conclusion: Although a large number of studies investigated the potential effect of biological treatment on postoperative outcomes, many re-
ported divergent results. There is a need for randomized controlled trials. Future studies should focus on the avoiding the weakness of prior studies 
we identified. Seeking collaborators and sharing information via Twitter was integral to widening the contributors/authors and peer review for this 
article and was an effective method of collaboration.
Key Words:  Crohn disease, inflammatory bowel disease, ulcerative colitis, biologic treatment, biologics, anti-TNF alpha, postoperative outcome, 
surgery.
INTRODUCTION
Biologic therapies have revolutionized the management 
of inflammatory bowel diseases (IBD), that is Crohn disease 
(CD) and ulcerative colitis (UC). Biologics, including antitumor 
necrosis factor-alpha agents (a-TNF), and more recently anti-
integrin and anti-IL-12/23 agents, are reserved for patients with 
moderate-to-severe disease activity or for patients who are med-
ically refractory to conventional therapy such as azathioprine, 
mercaptopurine, methotrexate, or corticosteroids. However, 
TNF is an important component of the immune defense 
mechanism and plays a role in wound healing through a dose-
dependent effect on angiogenesis1 and collagen synthesis.2–4 
Inhibition of TNF-mediated pathways may impair wound 
healing after surgery, thus theoretically increasing the risk of 
postoperative complications such as surgical site infection and 
anastomosis-related complications, although the latter has, to 
date, never been demonstrated in any clinical study or trial.
Despite having been used since 1998, the natural history 
of CD appears to be unaffected using a-TNF.5 Hence, the risk 
of surgery to treat refractory CD may not have changed in the 
era of biologics. The overall risk of surgery was 22% in a recent 
European study,6 and risk for second surgery is 28.7% based on 
meta-analysis of population-based studies.7 Furthermore, up to 
50% of CD patients have been exposed to an a-TNF at time of 
their first surgery.8 In UC, the risk of colectomy seems to have 
decreased in the era of biologics.9 It is not clear whether this 
change is related to the introduction of biologics or better pre-
operative optimization.
To date, there are 106 scientific papers assessing the effect 
of a-TNF therapy on postoperative outcome, with divergent 
conclusions. As such, there is a need to assess the current evi-
dence and to assess each studies strength and weakness, so as to 
help plan future studies with optimal design and methodology. 
Thus, the aim of this study was to assess the potential associa-
tion between preoperative exposure to biologics with postoper-
ative outcomes in IBD patients and to make recommendations 
for the optimal design of future studies.
METHOD
This study is a narrative review based on a published sys-
tematic review by one of the authors (A.E.).10 In this update, all el-
igible studies were included. No statistical analyses or bias control 
analyses were conducted because of the wide heterogeneity of the 
included studies. Biologic treatment was defined as treatment with 
a-TNF agents (eg, infliximab or adalimumab), integrin inhibitors 
(eg, vedolizumab), or IL-12/23 inhibitors (eg, ustekinumab).
WHAT DOES THIS ARTICLE ADD TO EXISTING 
LITERATURE AND WHAT IT DOES NOT ADD?
This study represents the most extensive literature re-
view done on the subject using a unique, social media-based, 
methodology. It identified all the studies published until 
September 30, 2018, analyzed these studies, described the 106 
studies, and attempted to answer these questions:
 1. Why these 106 studies reported divergent results?
 2. Why there are a large number of studies with severe limitations in 
methodology? Is this not a waste of resources?
 3. Can social media and internet connection improve research 
quality and facilitate optimal design of future studies?
To the best of our knowledge, this represents the first 
research project conducted using social media to recruit 
coauthors and paragraph-by-paragraph revision of the man-
uscript via the #OpenSourceResearch.
The authors would like to emphasize that:
 1. This is not a systematic review or meta-analysis because there 
are already many systematic reviews and meta-analysis about the 
subject with divergent conclusions.
 2. This is a case in point for surgical research. With such study, 
the authors hope that less temptation to conduct small series 
studies will be encountered and better cooperation in con-
ducting larger-scale studies will be encouraged to advance sur-
gical science.
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Aim
The aim of this review is to provide a case in point about 
surgical research by examining one subject in mintious details 
to identify the limitations of reported studies and attempt to 
lead the design of future studies.
Eligibility Criteria
Case–control and cohort studies were included irrespective 
of publication status, year of publication, or language. Included 
studies assessed patients with CD or UC undergoing laparoscopic 
or open abdominopelvic surgery. Based on pharmacokinetic 
studies, the intervention group included patients who received any 
type or dose of biologics within 3 months of surgery.
Outcome Measures
Outcome measures were assessed after 30  days of fol-
low-up. The outcomes were assessed as defined by the authors 
of the included studies.
Search Strategy and Method of Updating 
the Review
The search strategy is attached as a Supplementary 
Material. The search was prospectively updated by the authors 
using:
 1. Alerts from PubMed.gov.
 2. Alerts from researchgate.com (any citation of articles by authors).
 3. Alerts from relevant journals.
 4. Attending relevant conferences (European Society of ColoProctology 
[ESCP], European Crohn’s and Colitis Organization [ECCO], 
Association of Coloproctology of Great Britain and Ireland, 
American Society of Colon and Rectal Surgeons [ASCRS]).
 5. Following topical developments in the subject as the authors are re-
viewers in many international journals and are, or have been, members 
of guidelines committees for UC and CD with the following organiza-
tion: European Crohn’s and Colitis Organization, Crohn’s and Colitis 
Foundation, and the American Society of Colon and Rectal Surgeons.
 6. Contacting experts in the field using the Twitter #SoMe4Surgery 
hashtag. Many authors are expert in this subject (A.H., S.H., P.K., 
P.M., J.D., A.E., A.S., N.Y., S.W., see Supplementary Material with 
list of all authors). All the contributors were asked to update the list 
of the included articles using their Twitter network to ensure that all 
relevant studies are included. Two additional papers were identified 
via this mechanism.
Open Source Research Project
The paper was written in a collaborative method with au-
thors invited personally and through Twitter via the following 
hashtags (#OpenSourceResearch and #SoMe4Surgery). 
A Google document was created which was shared across so-
cial media and comments and edits were verified by the primary 
author to ensure accuracy and consistency. The manuscript was 
presented on Twitter in sequential posts by section. Each post 
contained 1–2 paragraphs of the manuscript modified to fit the 
limited space in Twitter and include powerpoint slides and im-
ages. This collaboration allowed this research and paper to be 
unique in the way it was written and edited.
Twitter offered a platform to engage researchers, to 
broaden the search, and to conduct scientific discussions.
The final draft was sent by email to all contributors for 
feedback prior to submission and the primary author (A.E.) 
completed the final draft which was then edited for grammar by 
a native English-speaking author (S.H.).
Twitter Analysis of the #OpenSourceResearch
Twitter is an American-based yet international online news 
and social networking service to which users post and interact with 
messages known as “tweets.” Tweets were originally restricted to 
140 characters, but this limit was doubled for all languages except 
Chinese, Japanese, and Korean. Registered users may post, like, 
and “retweet” tweets, but unregistered users can only read them. 
Users access Twitter through its website interface, short message 
service, or its mobile-device application software (“app”).
As this paper was written as a social media–based collab-
oration, it was important to capture social media activity as po-
tential source material for the paper and to assess the response to 
the idea of an open-source research paper, as well as to document 
the main influencers of these discussions. Data were collected 
through 2 tools—“Followthehashtag” for geographical mapping 
and gender split of tweeters, and “NodeXL” to document the 
networking interactions between tweeters and describe the inter-
actions between these tweeters (replies, retweets, and mentions of 
other tweeters). Both tools can be used to quantify the number of 
tweeters, retweeters, and tweets. Both tools also provide informa-
tion about individual tweets. Additional information is available 
at http://analytics.followthehashtag.com/#!/?id=dashboard and 
at https://www.smrfoundation.org/nodexl/.
RESULTS
We identified a total of 106 studies that investigated the 
impact of preoperative biological treatment on postoperative 
outcome in patients with IBD. The relation of a-TNF therapy 
with postoperative outcomes in patients with IBD has been in-
vestigated in 32 retrospective CD cohorts11–42 (CD with/without 
UC), in 16 retrospective cohorts (UC),43–58 3 prospective ones,59–61 
4 experimental studies,62–65 3 population-based studies,66–68 10 
narrative reviews,69–78 and 14 meta-analyses10, 79–89 making a total 
of 82 studies over the past 15 years (Tables 1–4). In addition, 
27 studies investigated this relation as part of other risk fac-
tors of unfavorable postoperative outcome, as well as studies 
with a focus on rheumatoid arthritis (Table 5). The 54 clinical 
studies, which included 32 retrospective cohorts of CD, 16 ret-
rospective cohorts of UC, 3 prospective cohorts of CD, and 3 
nation-based studies, are demonstrated in details in Tables 1–3. 
In total, these clinical studies have included 22,923 patients of 
whom 5501 (24%) were on preoperative biological treatment.
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TABLE 2. Clinical Studies About Type of Preoperative Biological Treatment in Patients With Crohn Disease, Ulcerative 
Colitis, and Indeterminate Colitis (Mixed Population Studies)
Author/Publication’s Year Cohort/Treated (3003/1234) Type of Biological Treatment Weeks Before Surgery
Observational retrospective studies
1 Kunitake25 et al (2008) 413/101 IFX 12
2 Regadas26et al (2010) 249/28 IFX 8
3 Rizzo27 et al (2011) 114/54 Anti-TNF 12 (and 4 wk)
4 Krane28 et al (2013) 518/142 IFX 12
5 Waterman29 et al (2013) 282/73 IFX, ADA 25
6 Lau30 et al (2015) 217/143 IFX, ADA, CZM Not specifieda
7 Alsaleh31 et al (2016) 47/47 IFX 12
8 Lightner32 et al (2016) 392/220 VDZ 12
9 Shwaartz33 et al (2016) 282/73 IFX, ADA, CZM 8
10 Yamada35 et al (2017) 443/193 IFX, ADA, VDZ 4
Prospective studies
11 El-Hussuna61 et al (2018) 46/18 IFX, ADA, CZM 12
aAbout 65% of patients in this cohort received anti-TNF-α therapy before surgery.
IFX, infliximab; ADA, adalimumab; CZM, cemizia; VDZ, vedolizumab; anti-TNF, antitumor necrosis factor agents.
TABLE 3. Clinical Studies About Type of Preoperative Biological Treatment in Patients With Ulcerative Colitis
Author/Publication’s Year Cohort/Treated (11,965/2181) Type of Biological Treatment Weeks Before Surgery
Observational retrospective studies
1 Selvasekar43 et al (2007) 301/47 IFX 8a
2 Schluender44 et al (2007) 151/17 IFX Up to 54
3 Mor51 et al (2008) 523/85 IFX Up to 37
4 Ferrante52 et al (2009) 141/22 IFX Up 12
5 Coquet-Reinier53 et al (2010) 26/13 IFX Up to 23
6 Gainsbury54 et al (2011) 81/29 IFX 12
7 Bregnbak55 et al (2012) 71/20 IFX 12
8 Kennedy98 et al (2012)b 38/11 IFX 8
9 Uchino57 et al (2013) 196/22 IFX 12
10 Eshuis58 et al (2013) 72/38 IFX Up to 32
11 Gu45 et al (2013) 181/25 IFX, ADA, CZM 12
12 Nelson46 et al (2014) 78/28 IFX 1
13 Zittan47 et al (2016) 562/196 Anti-TNF Up to 24
14 Kulaylat48 et al (2017) 2476/650 IFX, ADA, CZM 12
15 Lightner49 et al (2017) 150/150 VDZ 12
16 Ferrante50 et al (2017) 170/94 VDZ, anti-TNF 8–16
Nation-wide database study
17 Nørgård67 et al (2013) 1226/199 Anti-TNF 12
18 Ward68 et al (2017) 6225/753 Anti-TNF 12 (and 4 wk)
aOnly 49% of patients in the study cohort.
bPediatric age cohort.
IFX, infliximab; ADA, adalimumab; CZM, cemizia; VDZ, vedolizumab; anti-TNF, antitumor necrosis factor agents.
D
ow
nloaded from
 https://academ
ic.oup.com
/crohnscolitis360/article-abstract/1/3/otz021/5544997 by Aalborg U
niversity Library user on 05 February 2020
 Crohn’s & Colitis 360 • Volume XX, Number XX, XXXX 2019
6
Open Source Research Collaborating Group
How Confounding Factors Were Addressed in 
the Different Studies?
The included studies varied in the method in which they 
addressed potential confounding factors as type of medication, 
time internal between medication and surgery, drug concentra-
tion, presecence of antidrug antibodies. Here is an account of 
these confounding factors and how they were addressed in dif-
ferent studies.
Type of medication
Some studies defined the type of biological treatments 
(e.g. infliximab); others reported a broad category of treatment 
(e.g. a-TNF, including certolizumab pegol and golimumab) 
while a few studies included all biological treatments without 
any definition (Tables 1–3). This may influence the results as 
these agents differ in their efficacy, half-life, mechanism of 
action, pharmacodynamics and pharmacokinetics including 
bioavailability and elimination/excretion (in stool for example). 
Infliximab, for instance, is administered intravenously (IV), 
while adalimumab, certolizumab pegol, and golimumab are ad-
ministered subcutaneously (SC). Intravenous administration is 
associated with large volume, rapid central distribution with 
low variability in bioavailability. Absorption from SC adminis-
tration is slow, and it may induce more immunogenicity.90 The 
IBDResponse61 trial has drawn attention to this problem and 
challenged the results obtained from previous studies where a 
mix of biological treatment agents were registered.
Time interval between medication and surgical 
intervention
Most of the studies chose a 8- to 12-week interval from the 
last dose of a-TNF to the date of surgical surgery (Tables 1–3). 
This is mainly based on pharmacokinetics of infliximab (the 
most commonly used drug), assuming first-order elimination 
TABLE 4. Meta-analyses and Systematic Reviews That Investigated the Effect of Biological Treatment on Postoperative 
Outcome in Patients With Inflammatory Bowel Disease
Author/Publication’s Year Disease Primary Outcome
Systematic/narrative reviews
1 Subramanian69 et al (2006) CD and UC Postoperative complications
2 Ali70 et al (2012) CD and UC Postoperative complications
3 El-Hussuna71 et al (2014) CD Postoperative complications
4 Papaconstantinou72 et al (2014) CD Postoperative complications
5 Saab78 et al (2015) CD Postoperative complications
6 Holubar73 et al (2015) CD and UC Overall/infectious complications
7 Alexakis74 et al (2015) UC Colectomy and hospitalization rates
8 Chang75 et al (2015) CD Surgical complications
9 Kotze76 et al (2017) CD Postoperative complications
10 Engel77 et al (2017) CD and UC Postoperative complications
Meta-analyses
1 Yang116 et al (2009) UC Postoperative complications
2 Ehteshami-Afshar82 et al (2011) CD and UC Colectomy and hospitalization rates
3 Kopylov81 et al (2012) CD Colectomy and hospitalization rates
4 El-Hussuna10 et al (2013) CD Anastomotic complications
5 Billioud84 et al (2013) CD and UC Postoperative complications
6 Narula85 et al (2013) CD and UC Postoperative complications
7 Rosenfeld86 et al (2013) CD Postoperative complications
8 Yang116 et al (2014) CD Postoperative complications
9 Ahmed Ali87 et al (2014) CD Overall/infectious complications
10 Selvaggi120 et al (2015) UC Pouch-related postoperative complications
11 Waterland88 et al (2016) CD Infectious complications
12 Law89 et al (2018) CD and UC Overall/infectious complications
13 Xu80 et al (2018) CD Postoperative complications
14 Yung81 et al (2018) CD and UC Postoperative complications
It shows 12 reviews about CD, 9 about mixed population, and only 3 about UC.
D
ow
nloaded from
 https://academ
ic.oup.com
/crohnscolitis360/article-abstract/1/3/otz021/5544997 by Aalborg U
niversity Library user on 05 February 2020
Crohn’s & Colitis 360 • Volume XX, Number XX, XXXX 2019 
7
Open-Source Expert Panel Review
TA
BL
E 
5.
 C
lin
ic
al
 S
tu
di
es
 A
bo
ut
 R
is
k 
Fa
ct
or
s 
fo
r U
nf
av
or
ab
le
 P
os
to
pe
ra
tiv
e 
O
ut
co
m
e 
in
 P
at
ie
nt
s W
ith
 C
ro
hn
 D
is
ea
se
 a
nd
 U
lc
er
at
iv
e 
Co
lit
is
A
ut
ho
r/
P
ub
lic
at
io
n’
s 
Y
ea
r
D
is
ea
se
C
oh
or
t/
T
re
at
ed
 (
12
,8
30
/2
88
1)
T
yp
e 
of
 B
io
lo
gi
ca
l T
re
at
m
en
t
W
ee
ks
 B
ef
or
e 
Su
rg
er
y
O
bs
er
va
ti
on
al
 r
et
ro
sp
ec
ti
ve
 s
tu
di
es
1
Ie
sa
ln
ie
ks
12
1  e
t 
al
 (
20
08
)
C
D
28
2/
4
IF
X
8
2
Sa
m
pi
et
ro
12
2  e
t 
al
 (
20
09
)
C
D
39
3/
13
B
io
lo
gi
ca
l a
ge
nt
s 
(n
ot
 s
pe
ci
fie
d)
N
ot
 s
pe
ci
fie
d
3
C
an
ed
o1
23
 e
t 
al
 (
20
10
)
C
D
 a
nd
 U
C
21
3/
61
IF
X
, A
D
A
8
4
H
ol
ub
ar
12
4  e
t 
al
 (
20
10
)
C
D
92
/3
2
B
io
lo
gi
ca
l a
ge
nt
s 
(n
ot
 s
pe
ci
fie
d)
N
ot
 s
pe
ci
fie
d
5
D
e 
Si
lv
a1
25
 e
t 
al
 (
20
11
)
U
C
66
6/
58
IF
X
N
ot
 s
pe
ci
fie
d
6
M
as
ca
re
nh
as
12
6  e
t 
al
 (
20
12
)
C
D
93
/1
9
IF
X
, A
D
A
 a
nd
 o
th
er
s 
(n
ot
 s
pe
ci
fie
d)
12
7
R
is
s1
27
 e
t 
al
 (
20
12
)
C
D
18
2/
3
IF
X
1
8
T
zi
va
na
ki
s1
28
 e
t 
al
 (
20
12
)
C
D
20
7/
no
t 
st
at
ed
IF
X
N
ot
 s
pe
ci
fie
d
9
B
el
lo
lio
12
9  e
t 
al
 (
20
13
)
C
D
43
4/
42
B
io
lo
gi
ca
l a
ge
nt
s 
(n
ot
 s
pe
ci
fie
d)
N
ot
 s
pe
ci
fie
d
10
G
u1
30
 e
t 
al
 (
20
13
)
U
C
20
4/
73
A
nt
i-
T
N
F
-α
 (
no
t 
sp
ec
ifi
ed
)
N
ot
 s
pe
ci
fie
d
11
B
ar
te
ls
13
1  e
t 
al
 (
20
13
)
U
C
71
/1
6
A
nt
i-
T
N
F
-α
 (
no
t 
sp
ec
ifi
ed
)
N
ot
 s
pe
ci
fie
d
12
B
ew
tr
a1
32
 e
t 
al
 (
20
13
)
U
C
83
0/
65
IF
X
N
ot
 s
pe
ci
fie
d
13
H
ic
ks
13
3  e
t 
al
 (
20
14
)
U
C
17
9/
43
IF
X
N
ot
 s
pe
ci
fie
d
14
M
or
ar
13
4  e
t 
al
 (
20
15
)
C
D
14
2/
4
IF
X
, A
D
A
4
15
Z
uo
13
5  e
t 
al
 (
20
15
)
C
D
34
4/
8
IF
X
N
ot
 s
pe
ci
fie
d
16
F
eu
er
st
ei
n1
36
 e
t 
al
 (
20
15
)
U
C
20
9/
24
A
nt
i-
T
N
F
-α
 (
no
t 
sp
ec
ifi
ed
)
N
ot
 s
pe
ci
fie
d
17
L
i13
6  e
t 
al
 (
20
16
)
C
D
14
61
/1
90
B
io
lo
gi
ca
l a
ge
nt
s 
(n
ot
 s
pe
ci
fie
d)
N
ot
 s
pe
ci
fie
d
18
G
er
m
ai
n1
37
 e
t 
al
 (
20
16
)
C
D
13
7/
13
A
nt
i-
T
N
F
-α
 (
no
t 
sp
ec
ifi
ed
)
8
19
Y
am
am
ot
o1
38
 e
t 
al
 (
20
16
)
C
D
23
1/
79
IF
X
, A
D
A
8
20
Sa
ha
m
i13
9  e
t 
al
 (
20
16
)
U
C
64
0/
51
A
nt
i-
T
N
F
-α
 (
no
t 
sp
ec
ifi
ed
)
12
21
G
uo
14
0  e
t 
al
 (
20
17
)
C
D
11
8/
11
A
nt
i-
T
N
F
-α
 (
no
t 
sp
ec
ifi
ed
)
24
22
C
ol
la
bo
ra
ti
ve
10
1  (
20
17
)
C
D
37
5/
82
IF
X
, A
D
A
, C
Z
M
, a
nd
 o
th
er
s 
(n
ot
 s
pe
ci
fie
d)
12
23
D
ie
de
re
n1
41
 e
t 
al
 (
20
17
)
U
C
42
2/
14
A
nt
i-
T
N
F
-α
 (
no
t 
sp
ec
ifi
ed
)
12
24
G
al
at
a1
00
 e
t 
al
 (
20
18
)
C
D
30
5/
72
IF
X
, A
D
A
, g
ol
im
um
ab
, v
ed
oz
ul
im
ab
, a
nd
 o
th
er
s
4
25
H
ei
m
an
n1
42
 e
t 
al
 (
20
18
)
C
D
 a
nd
 U
C
10
00
/7
1
B
io
lo
gi
ca
l a
ge
nt
s 
(n
ot
 s
pe
ci
fie
d)
6
R
ev
ie
w
s
26
H
ua
ng
14
3  e
t 
al
 (
20
15
)
C
D
38
07
/1
83
3
B
io
lo
gi
ca
l a
ge
nt
s 
(n
ot
 s
pe
ci
fie
d)
N
ot
 s
pe
ci
fie
d
27
B
ed
dy
14
4  e
t 
al
 (
20
11
)
C
D
 a
nd
 U
C
N
ot
 s
ta
te
d
B
io
lo
gi
ca
l a
ge
nt
s 
(n
ot
 s
pe
ci
fie
d)
N
ot
 s
pe
ci
fie
d
In
 t
he
se
 s
tu
di
es
, b
io
lo
gi
ca
l t
re
at
m
en
t 
w
as
 a
na
ly
ze
d 
as
 p
ar
t 
of
 t
he
 r
is
k 
fa
ct
or
s 
in
 m
ul
ti
va
ri
at
e 
an
al
ys
is
.
IF
X
, i
nfl
ix
im
ab
; A
D
A
, a
da
lim
um
ab
; C
Z
M
, c
em
iz
ia
; a
nt
i-
T
N
F
-α
, a
nt
it
um
or
 n
ec
ro
si
s 
fa
ct
or
 a
lp
ha
 a
ge
nt
s.
D
ow
nloaded from
 https://academ
ic.oup.com
/crohnscolitis360/article-abstract/1/3/otz021/5544997 by Aalborg U
niversity Library user on 05 February 2020
 Crohn’s & Colitis 360 • Volume XX, Number XX, XXXX 2019
8
Open Source Research Collaborating Group
kinetics (Fig. 1), which may or may not be applicable; of note, 
trace levels of infliximab can be found up to 12 weeks after ad-
ministration.90 However, during this time, drug concentration 
and its efficacy can vary from a peak at the time of adminis-
tration to a trace level at the end of time interval (see the next 
section).
Drug concentration in the peripheral blood (serum 
levels of biological agents)
Drug concentration in the peripheral blood correlates 
with drug concentration in the inflamed tissue91 and it varies 
during the 12-week period prior to surgery with a peak at the 
time of administration and a fading to trace levels in the fol-
lowing weeks (Fig. 1). Drug concentration is essential for drug 
action and for the stimulation of antidrug antibody forma-
tion.90 Reporting biologic treatment at 12 weeks interval can 
therefore be misleading and interpretation of the results may 
differ. Only 4 studies investigated drug concentration in the pe-
ripheral blood.29, 30, 60, 61 These 4 studies reported the drug con-
centration at different time intervals using trough levels in the 
serum. These trough levels are measured by using enzyme-linked 
immunosorbent assay, and these levels may be decreased by 
leakage of the antibodies through inflamed bowel mucosa into 
the stool92 and/or deactivation by development of antibodies 
against the injected anti-TNF (antidrug antibodies).93 Fumery 
et al60 reported drug concentration of 76 of the 93 patients who 
received a-TNF treatment within a period of 12 weeks before 
surgery. The measurement of trough level was done on the day 
of surgery.60 Lau et al reported serum drug concentrations from 
samples drawn at varying preoperative time points in 143 pa-
tients with IBD treated with a-TNF.30
Waterman et al reported drug concentration in a subset 
of 19 patients with UC exposed to a-TNF treatment within 8 
weeks prior to surgery. The authors also reported antidrug anti-
bodies.29 Analysis by Waterman et al included patients exposed 
to a-TNF treatment within 180 days of surgery. El-Hussuna61 
et al reported in IBDResponse study drug concentration and 
antidrug antibodies for 18 patients with IBD. Samples were col-
lected within 24 hours before surgery as well as 6, 24, and 48 
hours after surgery providing a unique chance to examine the 
drug and antidrug antibodies in this group of patients.
Antidrug antibodies
The IBDResponse trial61 showed that some patients 
develop antidrug antibodies to a-TNF agents regardless of 
the route of administration (IV or SC). These antidrug anti-
bodies may reduce the efficacy of drugs. Misinterpretation of 
results in the studies where these antibodies were not meas-
ured cannot be dismissed. Only 2 studies29, 61 measured and re-
ported these antidrug antibodies. Concurrent administration 
of immunomodulators has been shown to reduce the formation 
of antidrug antibodies.90
How the Included Studies Adjusted for Potential 
Confounding Factors in Multivariate Analysis
Many researchers suspected confounding factors play 
a role and affect postoperative outcomes. These factors have a 
varying degree of influence on the postoperative outcome and 
with increasing influence by the number of concurrent risk fac-
tors. Some of these factors are well studied such as concurrent 
medications, whereas others are less studied such as preopera-
tive optimization, the latter which has been recently shown to 
have a strong influence on the postoperative outcome.94, 95 Three 
categories of confounding factors can be identified and have 
been studied:
Factors with questionable impact as shown by the 
studies that adjusted for these factors
 (a) Type of surgical intervention and access to abdominal cavity 
(studies of ileo-caecal resection,15, 19, 34, 60, 96 studies of different 
types of bowel resections with or without stricturoplasty,11–14, 16–18, 
22–25, 27–33, 36–40, 42, 59, 66, 97 and studies of ileostomy reversal.26 In patients 
with UC most of the studies reported postoperative outcome after 
subtotal colectomy,36, 43–46, 48, 55, 67, 68 completion prctectomy,57 ileal 
pouch-anal anastomosis,43–45, 48, 50, 51, 53, 54, 58, 98 and other procedures 
in addition to the above-mentioned.49
 (b) One third of studies adjusted for BMI.15, 16, 19, 24, 28, 29, 32, 33, 36, 38–40, 43, 45, 
49, 53, 54, 58–60, 96
 (c) Many studies adjusted for American Society of Anesthesiology 
score.14, 15, 33, 34, 36, 38, 45, 54, 59, 96 However, many studies reported comor-
bidity,19, 26–28, 32, 33, 36, 40, 45, 48, 53, 54, 67 but few used Charlson comorbidity 
score.16, 25, 66, 68
FIGURE 1. Graphical representation of the theoretical in vivo half-
lives of biologic agents used to treat CUC. Note this graph assumes 
first-order elimination pharmacokinetics. With permission from Stefan 
Holubar.
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 (d) Previous intestinal resections reported/adjusted for in 14 studies.12, 
14–16, 19, 23, 27, 28, 36, 39, 40, 60, 96, 99
 (e) Disease phenotype reported was reported in many studies.13–19, 22, 29, 
30, 34, 36, 38, 39, 59, 60, 97, 99
 (f) The affected bowel segment/length or disease location was re-
ported in 20 studies.12–15, 19, 27, 29, 36, 39, 44–46, 50, 58–60, 96, 97, 99
 (g) Duration of operation was reported in some studies.15, 23, 28, 36, 40, 42, 53, 
59, 96
 (h) Preoperative intra-abdominal sepsis (intra-abdominal abscess and/
or enteric fistula) was reported in 9 studies.13, 15, 16, 30, 34, 42, 59, 60, 96
 (i) Disease duration was reported in 15 studies12, 16, 18, 22, 27, 28, 35, 36, 38, 39, 46, 
58, 66, 67, 99
 (j) Urgency of surgical intervention was reported in one third of 
studies.12, 14–18, 25, 27, 29, 31, 33, 35–38, 40, 42, 45, 48, 50, 54, 59, 60, 68, 96, 97 Some studies 
excluded urgent/emergency operations to attain a homogenous 
group of elective surgical procedures.28, 38, 61
 (k) Surgeon’s experience (trainee, general surgeon, or colorectal sur-
geon) was reported in only 3 studies.30, 31, 96
 (l) The type/configuration of anastomosis or stoma construction was 
reported in several studies.14, 15, 19, 33, 45, 50, 54, 59, 96 One study included 
stricturoplasty in addition to primary anastomosis.14 Patients 
who received a diverting stoma were excluded in some studies,38, 42  
whereas other studies investigated these patients in subgroup 
analyses.59
 (m) Other factors such as intra-operative blood loss,37, 42 indication for 
surgery,12, 23, 25, 27, 29, 30, 34, 40, 50 multicenter versus single centre,27–30, 32, 33, 
35, 39, 42, 54 leucocytosis100 were reported but they appear to have min-
imum or no effect on the postoperative outcome. Close coopera-
tion between surgeon and gastroenterologist in presurgical decision 
making may have an impact on postoperative outcome,25, 101 but this 
factor is difficult to measure and not reported.
Factors expected to have large impact but were less 
well studied
 (a) Preoperative optimization: few studies reported interventions to 
optimize the patients prior to surgery, for example, nutritional sup-
port,15, 59, 60, 96 correction of anemia, or prehabilitation.
 (b) Use of a mechanical bowel preparation, which has been associated 
with anastomotic leaks rates, was reported in only one study.15
Factors which would be expected to have a large im-
pact on postoperative outcome
 (a) Concurrent medication was reported by almost all studies11–15, 17–19, 
22–25, 27–40, 43–46, 48–51, 53–55, 58–60, 66, 67, 96–98 except one population-based 
study on UC.68
 (b) Although nutritional status is widely known to influence 
postopertative outcomes,95, 94 it was only reported in some studies, 
whereas others did not report it.60, 66, 59, 24, 96, 19, Nutritional status 
was measured indirectly by assessment of serum albumin and/or 
haemoglobin11, 16, 18, 24, 25, 27, 29, 30, 32, 33, 35–37, 39, 40, 45, 49, 50, 55, 59, 60, 96–98 in those 
studies that adjusted for nutritional status. The IBDResponse 
trial61 used a validated standard score (nutritional risk screening 
which included weight loss more 10% of body weight) to assess 
nutritional status.
 (c) Smoking is well-documented risk factor of surgical site infection95 
however, with small sample size series (as in case of most studies) 
is it difficult to demonstrate statistical significance due to lack of 
power. Data on smoking were reported by some studies.11, 13–16, 18, 19, 
24, 28, 30, 32–36, 46, 49, 50, 55, 58–60, 68, 96, 97
 (d) Crohn Disease Activity Index (CDAI) was reported in 2 studies 
only,60, 99 whereas Harvey–Bradshaw Index was reported in one 
study.61 One study reported ACG severity of disease index,38 
whereas another one applied a local classification of disease ac-
tivity.28 In UC studies, one study used deprivation index,68 whereas 
others used a local disease activity index36, 48 or the Mayo score.55 
Regarding disease severity, there is a high likelihood that the most 
severely ill patients received anti-TNF, whereas the less ill patients 
did not. One study tried to compare similar groups where all pa-
tients received anti-TNF at any time during the disease course,14 
either at time of surgery or prior to (but withheld) versus after 
surgery.
How the Included Studies Reported Outcomes
Different methods were used to report the postopera-
tive outcome making the comparison of studies difficult. Some 
studies reported major and minor complications.16,19,22,23,37,39 
Others reported short-term (early) and long-term (late) post-
operative morbidity.12,23,28 A third category of studies reported 
septic/infectious11, 12, 14, 17, 19, 27, 31, 32, 35, 40, 43, 46, 54, 58, 59, 99 and nonseptic/
noninfectious complications. A few studies used the classifica-
tion of surgical complications versus medical complications,18, 
30, 44, 97 whereas other studies presented postoperative complica-
tions without classification or grading.14, 16, 24, 25, 27, 29, 33, 34, 49, 51, 60, 66, 
67, 98 However, there was increasing tendency to report outcomes 
according to Clavien–Dindo classification of postoperative 
complications.14, 19, 28, 30, 53, 59, 60, 96, 97 One study reported outcome 
when biological treatment was used after surgical intervention 
in CD.99
To the best of our knowledge, one study has used the 
Comprehensive Complications Index, a relatively new com-
posite outcome of any complication weighted by Clavien–
Dindo level.120 Interestingly, no difference in the length of stay 
(LOS) postoperatively was shown between patients treated with 
biological agents and those who did not receive treatment in 
the studies where LOS was reported. This was unexpected in 
studies that reported increased complication rates in patients 
treated with biological agents, as LOS will be longer in patients 
with postoperative complications.145
How the Different Studies Conducted Statistical 
Analyses
Most of the statistical analyses were done in similar 
fashion, that is, univariate analyses with chi-square test, Student 
t test, or Fisher exact test for categorical and Mann–Whitney, 
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Wilcoxon signed-rank tests for continuous variables. However, 
regarding multivariable analyses, many studies did not report 
what variables were entered in multivariate analyses, nor how 
these variables were chosen for the multivariate analyses.23, 38 
Errors in interpretation of statistical results were not uncommon 
for instance lack of adjustment for confounding factors.26,37
DISCUSSION
Despite the large number of studies available in the lit-
erature, the relationship between biologic treatment and post-
operative outcome in IBD is still controversial. During the last 
15 years, there have been improvements in study design, statis-
tical analyses, and sample size, moving from high risk of bias 
studies37 to more recently low risk of bias studies59; neverthe-
less, the topical debate and controversy continues. There are 3 
layers of complexity that made it difficult to reach definitive 
conclusions about the issue at hand:
 1. Difficulty of conducting clinical research compared with basic sci-
ence research. Clinical research is becoming more difficult due to 
the increased complexity of regulations and governance which can 
be far from patients’ interests.102 Up to half  of the approved studies 
by ethics committees are never published.103 It is well documented 
that clinical research attracts much less funding than basic science 
or translational research adding another challenge for outcomes 
research.104
 2. Difficulty in conducting research in surgery compared with medical 
specialties. Variation in surgical practice affects postoperative out-
come and leads to a strong confounding factor in surgical research. 
Few studies include surgeon experience or years from training.
 3. Difficulty in conducting IBD research. There is no doubt IBD is 
complex and heterogeneous; the treatment is complex as are the 
preoperative and postoperative assessments. To this end, a number 
of  groups have been working toward developed standardized out-
come sets to facilitate comparison of  data and effective meta-
analysis.105–108 Moreover, investigator-initiated trials often fail due 
to insufficient enrollment of  patients with IBD,100 and a priori 
power analyses are rarely reported. Only one third to half  of  pa-
tients with IBD need surgery during their lifetime (75% in CD8) 
making it even harder to recruit patients. Funding is a general 
problem in research, but it is more prominent in investigator-
initiated trials, especially in IBD. Having said this, it might be 
assumed that research in IBD surgery is very well planned to re-
duce poor quality and ensure best use of  resources. However, as of 
today, this is not the case which as this review demonstrates. Large 
amount of  resources were used in repeating studies with minor 
variations in design.
Crohn Disease
According to recently published guidelines,109–111 sur-
gery in patients with receiving a-TNF therapy may be associ-
ated with an increased risk of complications. Chronologically, 
the ASCRS 2015 clinical practice guideline on CD stated that 
patient receiving preoperative biologic treatment (ie, a-TNF or 
cyclosporine) should be considered for staged procedures be-
cause of postoperative complications risk.109 The authors sug-
gested final decision should be up to surgeon discretion using 
an individualized approach to each patient. A delay of at least 
8 weeks was proposed for elective whenever possible. The re-
commendations were graded as weak, quality of evidence 2C.
The ECCO published its third evidence-based CD con-
sensus in 2016,110 where the impact of biologic treatment for 
patients undergoing surgery was deemed unclear and contro-
versial. The authors based their statement on controversial 
data and advocated optimal preoperative preparation. A joint 
statement of the ESCP and ECCO considered a-TNF to be 
associated with risk of postoperative complications, particu-
larly sepsis (surgical site infections, abdominal abscesses, anas-
tomotic leaks) and higher readmissions.111 Nevertheless, no 
recommendation was made regarding the interval of biolog-
ical treatment withdrawal. All guidelines agree on the higher 
risk associated with long-term steroid therapy. Prednisolone 
20 mg daily or higher for >6 weeks was associated with higher 
postoperative surgical complications, especially when used 
in combination with biologic treatment.109–111 The American 
Gastroenterological Association (AGA) did not published spe-
cific recommendation on the clinical management of biological 
treatment prior to surgery.
Ulcerative Colitis
Published guidelines on the surgical management of UC 
includes the ECCO consensus.112 For acute situations, per-
forming staged procedures (ie, subtotal colectomy with end 
ileostomy as first stage)119 was advised for patients receiving bi-
ologic treatment (a-TNF) and/or Prednisolone 20 mg daily or 
higher for >6 weeks. Regarding preoperative management of 
biologic treatments, the increased risks of postoperative com-
plications, although controversial, were outlined, and single-
stage procto-colectomy with ileo-anal pouch reconstruction, 
for patients under a-TNF therapy, was not recommended.112 
Guidelines from the ASCRS published in 2014113 lacked defin-
itive consensus statement on the management of a-TNF prior 
to elective surgery for UC. According to the authors, literature 
was insufficient to assess the impact of biological treatment 
on postoperative outcomes and there was a claim for multi-
institutional larger studies.
There is no statistical model to predict the effect of var-
ious confounding factors on the postoperative outcomes in 
patients with IBD. It is nevertheless believed that the weight 
of these confounding factors in the final model is certainly dif-
ferent, and no standard recommendations for which variables 
to include in a multivariate model exists; thus, there is wide 
heterogeneity in model building, thus leading to varying and 
potentially noncomparable results and conclusions. Going for-
ward, propensity-score matching or inclusion of the propesity 
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score in the multivariate model, and other novel methods such 
as the difference-in-difference and use of instrumental variables 
all may play a role in reducing both the measured, and unmeas-
ured, bias and confounding in these studies.
Future Perspectives
ESCP conducted a snapshot audit in 2015 in which pa-
tients with CD undergoing ileo-caecal resection and right-
side colectomy where included, but this snapshot study did 
not provide a definitive answer regarding the effect of  bio-
logic treatment on postoperative outcomes.101 Clearly, there 
is a need for randomized controlled trials investigating the 
effect of  biological treatment on postoperative outcome in 
patients with IBD. The Pre-operative Continuation versus 
Discontinuation of  anti-TNF treatment in Patients with 
Crohn’s Disease (PCDantiPCD) trial protocol was presented 
in the 16th Nordic postgraduate course in colorectal surgery 
and at the ESCP 2018 trial session, and integrates many of  the 
points discussed above.
Measurement of drug concentration, antidrug anti-
bodies, and application of a standardized validated scoring sys-
tems for disease activity, nutritional status, and smoking will 
lead to better understanding of the effect/weight of different 
covariates in a model that describes how anti-TNF treatment 
influence the postoperative outcome. Meta-analysis of these 
randomized controlled trial will provide a solid evidence to 
eliminate the uncertainty of previous observational studies.
Limitations
This narrative updated review has the limitations of the 
studies included. It was not planned as a new systematic re-
view or meta-analysis; therefore, no statistical analysis was 
performed.
CONCLUSION
Many studies have investigated the effect of  biologic 
treatment on postoperative outcome using different method-
ological approaches (retrospective, prospective, population-
based, experimental, snapshot audit, and meta-analyses) with 
divergent results. Future studies should focus on the avoiding 
the above highlighted weakness of  the studies we reviewed. 
Consensus guidelines by the invested societies, such as ECCO, 
Crohn’s & Colitis Foundation (formerly known as the Crohn’s 
& Colitis Foundation of  America [CCFA]), and ESCP, are 
needed to guide future research. There is also a need for a 
randomized controlled trial to define the association, or 
lack thereof, between biological and adverse postoperative 
outcomes.
SUPPLEMENTARY DATA
Supplementary data are available at Crohn’s & Colitis 360 
online.
REFERENCES
1. Behm B, Babilas P, Landthaler M, et al. Cytokines, chemokines and growth fac-
tors in wound healing. J Eur Acad Dermatol Venereol. 2012;26:812–820.
2. Lin E, Lowry SF. Inflammatory cytokines in major surgery: a functional perspec-
tive. Intensive Care Med. 1999;25:255–257.
3. Park  JE, Barbul  A. Understanding the role of immune regulation in wound 
healing. Am J Surg. 2004;187:11S–16S.
4. Tsirogianni AK, Moutsopoulos NM, Moutsopoulos HM. Wound healing: immu-
nological aspects. Injury. 2006;37 (Suppl 1):S5–S12.
5. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, 
Loftus EV Jr. Surgery in a population-based cohort of Crohn’s disease from 
Olmsted county 1970–2004. AM J Gastrentrol. 2012;13:1133–1145.
6. Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s dis-
ease during the first 5 years after diagnosis in a European population-based incep-
tion cohort: an Epi-IBD study. Gut. 2018. pii: gutjnl-2017-315568. doi:10.1136/
gutjnl-2017-315568. [Epub ahead of print].
7. Frolkis  AD, Lipton  DS, Fiest  KM, et  al. Cumulative incidence of second in-
testinal resection in Crohn’s disease: a systematic review and meta-analysis of 
population-based studies. Am J Gastroenterol. 2014;109:1739–1748.
8. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tu-
mour necrosis factor antagonists on the need for surgery in newly diagnosed 
Crohn’s disease. Gut. 2011;60:930–936.
9. Colombel JF, Ricart E, Loftus EV Jr, et al. Management of Crohn’s disease of the 
ileoanal pouch with infliximab. Am J Gastroenterol. 2003;98:2239–2244.
10. El-Hussuna A, Krag A, Olaison G, et al. The effect of anti-tumor necrosis factor 
alpha agents on postoperative anastomotic complications in Crohn’s disease: a 
systematic review. Dis Colon Rectum. 2013;56:1423–1433.
11. Tay GS, Binion DG, Eastwood D, et al. Multivariate analysis suggests improved 
perioperative outcome in Crohn’s disease patients receiving immunomodulator 
therapy after segmental resection and/or strictureplasty. Surgery. 2003;134:565–
572; discussion 572.
12. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications 
are not increased in patients with Crohn’s disease treated perioperatively with 
infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878–883.
13. White  EC, Melmed  GY, Vasiliauskas  E, et  al. Does preoperative immunosup-
pression influence unplanned hospital readmission after surgery in patients with 
Crohn’s disease? Dis Colon Rectum. 2012;55:563–568.
14. Myrelid  P, Marti-Gallostra  M, Ashraf  S, et  al. Complications in surgery for 
Crohn’s disease after preoperative antitumour necrosis factor therapy. Br J Surg. 
2014;101:539–545.
15. Serradori  T, Germain  A, Scherrer  ML, et  al. The effect of immune therapy 
on surgical site infection following Crohn’s disease resection. Br J Surg. 
2013;100:1089–1093.
16. Syed  A, Cross  RK, Flasar  MH. Anti-tumor necrosis factor therapy is associ-
ated with infections after abdominal surgery in Crohn’s disease patients. Am J 
Gastroenterol. 2013;108:583–593.
17. Bafford AC, Powers S, Ha C, et al. Immunosuppressive therapy does not increase 
operative morbidity in patients with Crohn’s disease. J Clin Gastroenterol. 
2013;47:491–495.
18. Kotze PG, Saab MP, Saab B, et al. Tumor necrosis factor alpha inhibitors did 
not influence postoperative morbidity after elective surgical resections in Crohn’s 
disease. Dig Dis Sci. 2017;62:456–464.
19. Jouvin I, Lefevre JH, Creavin B, et al.; Saint-Antoine IBD Network. Postoperative 
morbidity risks following ileocolic resection for Crohn’s disease treated with anti-
TNF alpha therapy: a retrospective study of 360 patients. Inflamm Bowel Dis. 
2018;24:422–432.
20. Kotze PG, Ludvig JC, Teixeira FV, et al. Disease duration did not influence the 
rates of loss of efficacy of the anti-TNF therapy in Latin American Crohn’s dis-
ease patients. Digestion. 2015;91:158–163.
21. Shim  HH, Ma  C, Kotze  PG, et  al. Preoperative ustekinumab treatment is not 
associated with increased postoperative complications in Crohn’s disease: a 
Canadian Multi-Centre Observational Cohort Study. J Can Assoc Gastroenterol. 
2018;1:115–123.
22. Zimmerman  LA, Saites  CG, Bairdain  S, et  al. Postoperative complications in 
children with Crohn disease treated with infliximab. J Pediatr Gastroenterol Nutr. 
2016;63:352–356.
23. Marchal L, D’Haens G, Van Assche G, et al. The risk of post-operative compli-
cations associated with infliximab therapy for Crohn’s disease: a controlled cohort 
study. Aliment Pharmacol Ther. 2004;19:749–754.
24. Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in ustekinumab-
treated patients undergoing abdominal operations for Crohn’s disease. J Crohns 
Colitis. 2018;12:402–407.
25. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab 
in patients with Crohn’s disease and ulcerative colitis is not associated with an 
increased rate of postoperative complications. J Gastrointest Surg. 2008;12:1730–
1736; discussion 1736.
26. Regadas  FS, Pinto  RA, Murad-Regadas  SM, et  al. Short-term outcome of 
infliximab and other medications on patients with inflammatory bowel disease 
undergoing ileostomy reversal. Colorectal Dis. 2011;13:555–560.
D
ow
nloaded from
 https://academ
ic.oup.com
/crohnscolitis360/article-abstract/1/3/otz021/5544997 by Aalborg U
niversity Library user on 05 February 2020
 Crohn’s & Colitis 360 • Volume XX, Number XX, XXXX 2019
12
Open Source Research Collaborating Group
27. Rizzo G, Armuzzi A, Pugliese D, et al. Anti-TNF-alpha therapies do not increase 
early postoperative complications in patients with inflammatory bowel disease. 
An Italian single-center experience. Int J Colorectal Dis. 2011;26:1435–1444.
28. Krane MK, Allaix ME, Zoccali M, et al. Preoperative infliximab therapy does not 
increase morbidity and mortality after laparoscopic resection for inflammatory 
bowel disease. Dis Colon Rectum. 2013;56:449–457.
29. Waterman M, Xu W, Dinani A, et al. Preoperative biological therapy and short-
term outcomes of abdominal surgery in patients with inflammatory bowel dis-
ease. Gut. 2013;62:387–394.
30. Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-
TNFα therapy levels on early postoperative outcomes in inflammatory bowel dis-
ease surgery. Ann Surg. 2015;261:487–496.
31. Alsaleh  A, Gaidos  JK, Kang  L, et  al. Timing of last preoperative dose of 
infliximab does not increase postoperative complications in inflammatory bowel 
disease patients. Dig Dis Sci. 2016;61:2602–2607.
32. Lightner  AL, Raffals  LE, Mathis  KL, et  al. Postoperative outcomes in 
vedolizumab-treated patients undergoing abdominal operations for inflammatory 
bowel disease. J Crohns Colitis. 2017;11:185–190.
33. Shwaartz C, Fields AC, Sobrero M, et  al. Effect of anti-TNF agents on post-
operative outcomes in inflammatory bowel disease patients: a single institution 
experience. J Gastrointest Surg. 2016;20:1636–1642.
34. Appau  KA, Fazio  VW, Shen  B, et  al. Use of infliximab within 3  months of 
ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s 
patients. J Gastrointest Surg. 2008;12:1738–1744.
35. Yamada A, Komaki Y, Patel N, et al. Risk of postoperative complications among 
inflammatory bowel disease patients treated preoperatively with vedolizumab. Am 
J Gastroenterol. 2017;112:1423–1429.
36. Uchino M, Ikeuchi H, Matsuoka H, et al. Risk factors for surgical site infection 
and association with infliximab administration during surgery for Crohn’s dis-
ease. Dis Colon Rectum. 2013;56:1156–1165.
37. Indar AA, Young-Fadok TM, Heppell J, et al. Effect of perioperative immuno-
suppressive medication on early outcome in Crohn’s disease patients. World J 
Surg. 2009;33:1049–1052.
38. Nasir BS, Dozois EJ, Cima RR, et al. Perioperative anti-tumor necrosis factor 
therapy does not increase the rate of early postoperative complications in Crohn’s 
disease. J Gastrointest Surg. 2010;14:1859–1865; discussion 1865.
39. Kasparek  MS, Bruckmeier  A, Beigel  F, et  al. Infliximab does not affect post-
operative complication rates in Crohn’s patients undergoing abdominal surgery. 
Inflamm Bowel Dis. 2012;18:1207–1213.
40. Canedo J, Lee SH, Pinto R, et al. Surgical resection in Crohn’s disease: is immu-
nosuppressive medication associated with higher postoperative infection rates? 
Colorectal Dis. 2011;13:1294–1298.
41. Regueiro  M, El-Hachem  S, Kip  KE, et  al. Postoperative infliximab is not as-
sociated with an increase in adverse events in Crohn’s disease. Dig Dis Sci. 
2011;56:3610–3615.
42. El-Hussuna  A, Andersen  J, Bisgaard  T, et  al. Biologic treatment or 
immunomodulation is not associated with postoperative anastomotic com-
plications in abdominal surgery for Crohn’s disease. Scand J Gastroenterol. 
2012;47:662–668.
43. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term 
complications in patients undergoing operation for chronic ulcerative colitis. J 
Am Coll Surg. 2007;204:956–962; discussion 962.
44. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical 
morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis 
Colon Rectum. 2007;50:1747–1753.
45. Gu J, Remzi FH, Shen B, et al. Operative strategy modifies risk of pouch-related 
outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis 
factor-α therapy. Dis Colon Rectum. 2013;56:1243–1252.
46. Nelson R, Liao C, Fichera A, et al. Rescue therapy with cyclosporine or infliximab 
is not associated with an increased risk for postoperative complications in pa-
tients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel 
Dis. 2014;20:14–20.
47. Zittan  E, Milgrom  R, Ma  GW, et  al. Preoperative anti-tumor necrosis factor 
therapy in patients with ulcerative colitis is not associated with an increased risk 
of infectious and noninfectious complications after ileal pouch-anal anastomosis. 
Inflamm Bowel Dis. 2016;22:2442–2447.
48. Kulaylat  AS, Kulaylat  AN, Schaefer  EW, et  al. Association of preopera-
tive anti-tumor necrosis factor therapy with adverse postoperative outcomes 
in patients undergoing abdominal surgery for ulcerative colitis. JAMA Surg. 
2017;152:e171538.
49. Lightner  AL, McKenna  NP, Moncrief  S, et  al. Surgical outcomes in 
vedolizumab-treated patients with ulcerative colitis. Inflamm Bowel Dis. 
2017;23:2197–2201.
50. Ferrante  M, de  Buck  van  Overstraeten  A, Schils  N, et  al. Perioperative use 
of vedolizumab is not associated with postoperative infectious complica-
tions in patients with ulcerative colitis undergoing colectomy. J Crohns Colitis. 
2017;11:1353–1361.
51. Mor  IJ, Vogel  JD, da  Luz  Moreira  A, et  al. Infliximab in ulcerative colitis 
is associated with an increased risk of  postoperative complications after re-
storative proctocolectomy. Dis Colon Rectum. 2008;51:1202–1207; discussion 
1207.
52. Ferrante  M, D’Hoore  A, Vermeire  S, et  al. Corticosteroids but not infliximab 
increase short-term postoperative infectious complications in patients with ulcer-
ative colitis. Inflamm Bowel Dis. 2009;15:1062–1070.
53. Coquet-Reinier  B, Berdah  SV, Grimaud  JC, et  al. Preoperative infliximab 
treatment and postoperative complications after laparoscopic restorative 
proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg 
Endosc. 2010;24:1866–1871.
54. Gainsbury ML, Chu DI, Howard LA, et al. Preoperative infliximab is not asso-
ciated with an increased risk of short-term postoperative complications after re-
storative proctocolectomy and ileal pouch-anal anastomosis. J Gastrointest Surg. 
2011;15:397–403.
55. Bregnbak D, Mortensen C, Bendtsen F. Infliximab and complications after colec-
tomy in patients with ulcerative colitis. J Crohns Colitis. 2012;6:281–286.
56. Jones GR, Kennedy NA, Lees CW, et al. Systematic review: the use of thiopurines 
or anti-TNF in post-operative Crohn’s disease maintenance – progress and pro-
spects. Aliment Pharmacol Ther. 2014;39:1253–1265.
57. Uchino M, Ikeuchi H, Matsuoka H, et al. Infliximab administration prior to sur-
gery does not increase surgical site infections in patients with ulcerative colitis. Int 
J Colorectal Dis. 2013;28:1295–1306.
58. Eshuis  EJ, Al  Saady  RL, Stokkers  PC, et  al. Previous infliximab therapy and 
postoperative complications after proctocolectomy with ileum pouch anal anas-
tomosis. J Crohns Colitis. 2013;7:142–149.
59. Brouquet A, Maggiori L, Zerbib P, et al.; GETAID Chirurgie Group. Anti-TNF 
therapy is associated with an increased risk of postoperative morbidity after sur-
gery for ileocolonic Crohn disease: results of a prospective nationwide cohort. 
Ann Surg. 2018;267:221–228.
60. Fumery M, Seksik P, Auzolle C, et al.; REMIND Study Group Investigators. 
Postoperative complications after ileocecal resection in Crohn’s dis-
ease: a prospective study from the REMIND Group. Am J Gastroenterol. 
2017;112:337–345.
61. El-Hussuna A, Qvist N, Zangenberg MS, et al. No effect of anti-TNF-α agents 
on the surgical stress response in patients with inflammatory bowel disease 
undergoing bowel resections: a prospective multi-center pilot study. BMC Surg. 
2018;18:91.
62. Ploug  T, Andersen  K, Hansen  K, et  al. Influence of adalimumab treatment 
on anastomotic strength, degree of inflammation, and collagen formation: 
an experimental study on the small intestine of rabbits. Inflamm Bowel Dis. 
2013;19:254–258.
63. Strebel K, Nielsen SR, Biagini M, et al. Effect of Humira® on intestinal anasto-
motic response in rabbits. J Invest Surg. 2015;28:167–172.
64. Myrelid  P, Salim  SY, Darby  T, et  al. Effects of anti-inflammatory therapy on 
bursting pressure of colonic anastomosis in murine dextran sulfate sodium in-
duced colitis. Scand J Gastroenterol. 2015;50:991–1001.
65. Ågren MS, Andersen TL, Andersen L, et al. Nonselective matrix metalloproteinase 
but not tumor necrosis factor-α inhibition effectively preserves the early critical 
colon anastomotic integrity. Int J Colorectal Dis. 2011;26:329–337.
66. Nørgård BM, Nielsen J, Qvist N, et al. Pre-operative use of anti-TNF-α agents 
and the risk of post-operative complications in patients with Crohn’s disease – a 
nationwide cohort study. Aliment Pharmacol Ther. 2013;37:214–224.
67. Nørgård BM, Nielsen J, Qvist N, et al. Pre-operative use of anti-TNF-α agents 
and the risk of post-operative complications in patients with ulcerative colitis – a 
nationwide cohort study. Aliment Pharmacol Ther. 2012;35:1301–1309.
68. Ward ST, Mytton J, Henderson L, et al. Anti-TNF therapy is not associated with 
an increased risk of post-colectomy complications, a population-based study. 
Colorectal Dis. 2018;20:416–423.
69. Subramanian  V, Pollok  RC, Kang  JY, et  al. Systematic review of postopera-
tive complications in patients with inflammatory bowel disease treated with 
immunomodulators. Br J Surg. 2006;93:793–799.
70. Ali  T, Yun  L, Rubin  DT. Risk of post-operative complications associated 
with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol. 
2012;18:197–204.
71. El-Hussuna A, Theede K, Olaison G. Increased risk of post-operative complica-
tions in patients with Crohn’s disease treated with anti-tumour necrosis factor α 
agents – a systematic review. Dan Med J. 2014;61:A4975.
72. Papaconstantinou I, Zeglinas C, Gazouli M, et al. The impact of peri-operative 
anti-TNF treatment on anastomosis-related complications in Crohn’s disease pa-
tients. A critical review. J Gastrointest Surg. 2014;18:1216–1224.
73. Holubar SD, Holder-Murray J, Flasar M, et al. Anti-tumor necrosis factor-α an-
tibody therapy management before and after intestinal surgery for inflammatory 
bowel disease: a CCFA position paper. Inflamm Bowel Dis. 2015;21:2658–2672.
74. Alexakis C, Pollok RC. Impact of thiopurines and anti-tumour necrosis factor 
therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. 
World J Gastrointest Surg. 2015;7:360–369.
D
ow
nloaded from
 https://academ
ic.oup.com
/crohnscolitis360/article-abstract/1/3/otz021/5544997 by Aalborg U
niversity Library user on 05 February 2020
Crohn’s & Colitis 360 • Volume XX, Number XX, XXXX 2019 
13
Open-Source Expert Panel Review
75. Chang MI, Cohen BL, Greenstein AJ. A review of the impact of biologics on 
surgical complications in Crohn’s disease. Inflamm Bowel Dis. 2015;21:1472–1477.
76. Kotze PG, Ghosh S, Bemelman WA, et al. Preoperative use of anti-tumor ne-
crosis factor therapy in Crohn’s disease: promises and pitfalls. Intest Res. 
2017;15:160–165.
77. Engel  T, Ungar  B, Yung  DE, et  al. Vedolizumab in IBD-lessons from real-
world experience; a systematic review and pooled analysis. J Crohns Colitis. 
2018;12:245–257.
78. Saab M, Saab B, Olandoski M, et al. Impacto dos anti-TNF nas complicações 
pós-operatórias na doença de Crohn: Uma revisão. J Coloproctol. 
2015;35:128–136.
79. Yang ZP, Hong L, Wu Q, et  al. Preoperative infliximab use and postoperative 
complications in Crohn’s disease: a systematic review and meta-analysis. Int J 
Surg. 2014;12:224–230.
80. Xu Y, Yang L, An P, Zhou B, Liu G. Meta-analysis: The influence of preoperative 
infliximab use on postoperative complications of Crohn’s disease. Inflamm Bowel 
Dis. 2019;25:261–269. doi:10.1093/ibd/izy246.
81. Yung DE, Horesh N, Lightner AL, et al. Systematic review and meta-analysis: 
vedolizumab and postoperative complications in inflammatory bowel disease. 
Inflamm Bowel Dis. 2018;24:2327–2338.
82. Ehteshami-Afshar S, Nikfar S, Rezaie A, et al. A systematic review and meta-
analysis of the effects of infliximab on the rate of colectomy and post-operative 
complications in patients with inflammatory bowel disease. Arch Med Sci. 
2011;7:1000–1012.
83. Kopylov U, Ben-Horin S, Zmora O, et al. Anti-tumor necrosis factor and post-
operative complications in Crohn’s disease: systematic review and meta-analysis. 
Inflamm Bowel Dis. 2012;18:2404–2413.
84. Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy 
and postoperative complications in inflammatory bowel diseases: a meta-analysis. 
J Crohns Colitis. 2013;7:853–867.
85. Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-TNFα 
treatment and post-operative complications in patients with inflammatory bowel 
disease. Aliment Pharmacol Ther. 2013;37:1057–1064.
86. Rosenfeld G, Qian H, Bressler B. The risks of post-operative complications fol-
lowing pre-operative infliximab therapy for Crohn’s disease in patients under-
going abdominal surgery: a systematic review and meta-analysis. J Crohns Colitis. 
2013;7:868–877.
87. Ahmed Ali U, Martin ST, Rao AD, et al. Impact of preoperative immunosup-
pressive agents on postoperative outcomes in Crohn’s disease. Dis Colon Rectum. 
2014;57:663–674.
88. Waterland P, Athanasiou T, Patel H. Post-operative abdominal complications in 
Crohn’s disease in the biological era: systematic review and meta-analysis. World 
J Gastrointest Surg. 2016;8:274–283.
89. Law CCY, Narula A, Lightner AL, et al. Systematic review and meta-analysis: 
preoperative vedolizumab treatment and postoperative complications in patients 
with inflammatory bowel disease. J Crohns Colitis. 2018;12:538–545.
90. Vande  Casteele  N, Gils  A. Pharmacokinetics of anti-TNF monoclonal anti-
bodies in inflammatory bowel disease: adding value to current practice. J Clin 
Pharmacol. 2015;55 Suppl 3:S39–50. doi:10.1002/jcph.374 
91. Yoshihara T, Shinzaki S, Kawai S, et al. Tissue drug concentrations of anti-tumor 
necrosis factor agents are associated with the long-term outcome of patients with 
Crohn’s disease. Inflamm Bowel Dis. 2017;23:2172–2179.
92. Brandse JF, Van Den Brink GR, Wildenberg ME, et al. Loss of infliximab into 
feces is associated with lack of response to therapy in patients with severe ulcera-
tive colitis. Gastroenterology. 2015;149:350–355.e2.
93. Gorovits B, Baltrukonis DJ, Bhattacharya I, et al. Immunoassay methods used 
in clinical studies for the detection of anti-drug antibodies to adalimumab and 
infliximab. Clin Exp Immunol. 2018;192:348–365.
94. El-Hussuna A, Iesalnieks I, Horesh N, et al. The effect of pre-operative optimiza-
tion on post-operative outcome in Crohn’s disease resections. Int J Colorectal Dis. 
2017;32:49–56.
95. Zangenberg MS, Horesh N, Kopylov U, et al. Preoperative optimization of pa-
tients with inflammatory bowel disease undergoing gastrointestinal surgery: a sys-
tematic review. Int J Colorectal Dis. 2017;32:1663–1676.
96. 2015 European Society of  Coloproctology collaborating group. Risk factors 
for unfavourable postoperative outcome in patients with Crohn’s disease under-
going right hemicolectomy or ileocaecal resection An international audit by 
ESCP and S-ECCO. Colorectal Dis. 2017. doi:10.1111/codi.13889. [Epub ahead 
of  print].
97. Kotze  PG, Magro  DO, Martinez  CAR, et  al. Adalimumab and postoperative 
complications of elective intestinal resections in Crohn’s disease: a propensity 
score case-matched study. Color Dis. 2018;20:211–218.
98. Kennedy R, Potter DD, Moir C, et al. Pediatric chronic ulcerative colitis: does 
infliximab increase post-ileal pouch anal anastomosis complications? J Pediatr 
Surg. 2012;47:199–203.
99. Regueiro  M, El-Hachem  S, Kip  KE, et  al. Postoperative infliximab is not as-
sociated with an increase in adverse events in Crohn’s disease. Dig Dis Sci. 
2011;56:3610–3615.
100. Galata C, Weiss C, Hardt J, et al. Risk factors for early postoperative complica-
tions and length of hospital stay in ileocecal resection and right hemicolectomy for 
Crohn’s disease: a single-center experience. Int J Colorectal Dis. 2018;33:937–945.
101. 2015 European Society of Coloproctology Collaborating Group. Risk factors for 
unfavourable postoperative outcome in patients with Crohn’s disease undergoing 
right hemicolectomy or ileocaecal resection. An international audit by ESCP and 
S-ECCO. Color Dis. 2018;20:219–227.
102. Salman RA, Beller E, Kagan J, et al. NIH public access regulation and manage-
ment. Lancet. 2014;383:176–185.
103. Blümle A, Meerpohl JJ, Schumacher M, et al. Fate of clinical research studies 
after ethical approval – follow-up of study protocols until publication. PLoS One. 
2014;9:e87184.
104. Rygård  SL, Kjær  MN, Perner  A. Statens investering i kliniske forsøg. Ugeskr 
Læger 2018;180:V09170645.
105. Kim AH, Roberts C, Feagan BG, et  al. Developing a standard set of patient-
centred outcomes for inflammatory bowel disease – an international, cross-
disciplinary consensus. J Crohns Colitis. 2018;12:408–418.
106. Ma C, Panaccione R, Fedorak RN, et al. A systematic review for the develop-
ment of a core outcome set for ulcerative colitis clinical trials. Clin Gastroenterol 
Hepatol. 2017;16:637–647.e13.
107. Schlessinger DI, Iyengar S, Yanes AF, et al. Development of a core outcome set 
for clinical trials in basal cell carcinoma: study protocol for a systematic review 
of the literature and identification of a core outcome set using a Delphi survey. 
Trials. 2017;18:490.
108. Sahnan K, Tozer PJ, Adegbola SO, et al.; ENiGMA Collaborators. Developing a 
core outcome set for fistulising perianal Crohn’s disease. Gut. 2019;68:226–238.
109. Strong S, Steele SR, Boutrous M, et al.; Clinical Practice Guidelines Committee 
of the American Society of Colon and Rectal Surgeons. Clinical practice 
guideline for the surgical management of Crohn’s disease. Dis Colon Rectum. 
2015;58:1021–1036.
110. Gionchetti P, Dignass A, Danese S, et al.; ECCO. 3rd European evidence-based 
consensus on the diagnosis and management of Crohn’s disease 2016: part 2: sur-
gical management and special situations. J Crohns Colitis. 2017;11:135–149.
111. Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP consensus 
on surgery for Crohn’s disease. J Crohns Colitis. 2018;12:1–16.
112. Magro  F, Gionchetti  P, Eliakim  R, et  al.; European Crohn’s and Colitis 
Organisation [ECCO]. Third European evidence-based consensus on diag-
nosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-
intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal 
pouch disorders. J Crohns Colitis. 2017;11:649–670.
113. Ross  H, Steele  SR, Varma  M, et  al.; Standards Practice Task Force of the 
American Society of Colon and Rectal Surgeons. Practice parameters for the sur-
gical treatment of ulcerative colitis. Dis Colon Rectum. 2014;57:5–22.
114. Claxton K, Griffin S, Koffijberg H, et al. How to estimate the health benefits of 
additional research and changing clinical practice. BMJ. 2015;351:h5987.
115. Yang Z, Wu Q, Wu K, et al. Meta-analysis: pre-operative infliximab treatment 
and short-term post-operative complications in patients with ulcerative colitis. 
Aliment Pharmacol Ther. 2010;31:486–492.
116. Yang ZP, Hong L, Wu Q, et  al. Preoperative infliximab use and postoperative 
complications in Crohn’s disease: a systematic review and meta-analysis. Int J 
Surg. 2014;12:224–230.
117. Hajibandeh S, Hajibandeh S, Kennedy-Dalby A, et al. Purse-string skin closure 
versus linear skin closure techniques in stoma closure: a comprehensive meta-
analysis with trial sequential analysis of randomised trials. Int J Colorectal Dis. 
2018;33:1319–1332.
118. Clavien PA, Puhan MA. Measuring and achieving the best possible outcomes in 
surgery. Br J Surg. 2017;104:1121–1122.
119. Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: pre-operative infliximab treatment 
and short-term post-operative complications in patients with ulcerative colitis. 
Aliment Pharmacol Ther. 2010;31:486–492.
120. Selvaggi  F, Pellino  G, Canonico  S, et  al. Effect of preoperative biologic drugs 
on complications and function after restorative proctocolectomy with primary 
ileal pouch formation: systematic review and meta-analysis. Inflamm Bowel Dis. 
2015;21:79–92.
121. Iesalnieks I, Kilger A, Glass H, et al. Intraabdominal septic complications fol-
lowing bowel resection for Crohn’s disease: detrimental influence on long-term 
outcome. Int J Colorectal Dis. 2008;23:1167–1174.
122. Sampietro GM, Corsi F, Maconi G, et al. Prospective study of long-term results 
and prognostic factors after conservative surgery for small bowel Crohn’s disease. 
Clin Gastroenterol Hepatol. 2009;7:183–191; quiz 125.
123. Canedo J, Pinto RA, Regadas S, et al. Laparoscopic surgery for inflammatory 
bowel disease: does weight matter? Surg Endosc. 2010;24:1274–1279.
124. Holubar  SD, Dozois  EJ, Privitera  A, et  al. Minimally invasive colec-
tomy for Crohn’s colitis: a single institution experience. Inflamm Bowel Dis. 
2010;16:1940–1946.
125. de  Silva  S, Ma  C, Proulx  MC, et  al. Postoperative complications and mor-
tality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 
2011;9:972–980.
D
ow
nloaded from
 https://academ
ic.oup.com
/crohnscolitis360/article-abstract/1/3/otz021/5544997 by Aalborg U
niversity Library user on 05 February 2020
 Crohn’s & Colitis 360 • Volume XX, Number XX, XXXX 2019
14
Open Source Research Collaborating Group
126. Mascarenhas C, Nunoo R, Asgeirsson T, et al. Outcomes of ileocolic resection 
and right hemicolectomies for Crohn’s patients in comparison with non-Crohn’s 
patients and the impact of perioperative immunosuppressive therapy with 
biologics and steroids on inpatient complications. Am J Surg. 2012;203:375–378; 
discussion 378.
127. Riss S, Bittermann C, Schwameis K, et al. Determinants for postoperative com-
plications after laparoscopic intestinal resection for Crohn’s disease. Surg Endosc. 
2012;26:933–938.
128. Tzivanakis  A, Singh  JC, Guy  RJ, et  al. Influence of risk factors on the safety 
of ileocolic anastomosis in Crohn’s disease surgery. Dis Colon Rectum. 
2012;55:558–562.
129. Bellolio F, Cohen Z, Macrae HM, et al. Outcomes following surgery for perfor-
ating Crohn’s disease. Br J Surg. 2013;100:1344–1348.
130. Gu J, Stocchi L, Remzi F, et al. Factors associated with postoperative morbidity, 
reoperation and readmission rates after laparoscopic total abdominal colectomy 
for ulcerative colitis. Colorectal Dis. 2013;15:1123–1129.
131. Bartels SA, Gardenbroek TJ, Bos L, et al. Prolonged preoperative hospital stay 
is a risk factor for complications after emergency colectomy for severe colitis. 
Colorectal Dis. 2013;15:1392–1398.
132. Bewtra M, Newcomb CW, Wu Q, et al. Mortality associated with medical therapy 
versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med. 
2015;163:262–270.
133. Hicks CW, Hodin RA, Bordeianou L. Semi-urgent surgery in hospitalized pa-
tients with severe ulcerative colitis does not increase overall J-pouch complica-
tions. Am J Surg. 2014;207:281–287.
134. Morar PS, Hodgkinson JD, Thalayasingam S, et al. Determining predictors for 
intra-abdominal septic complications following ileocolonic resection for Crohn’s 
disease-considerations in pre-operative and peri-operative optimisation tech-
niques to improve outcome. J Crohns Colitis. 2015;9:483–491.
135. Zuo  L, Li  Y, Wang  H, et  al. A practical predictive index for intra-abdominal 
septic complications after primary anastomosis for Crohn’s disease: change in 
C-reactive protein level before surgery. Dis Colon Rectum. 2015;58:775–781.
136. Li Y, Stocchi L, Cherla D, et al. Association of preoperative narcotic use with 
postoperative complications and prolonged length of hospital stay in patients 
with Crohn disease. JAMA Surg. 2016;151:726–734.
137. Germain  A, Guéant  RM, Chamaillard  M, et  al. NOD2 gene variant is a risk 
factor for postoperative complications in patients with Crohn’s disease: a genetic 
association study. Surgery. 2016;160:74–80.
138. Yamamoto  T, Spinelli  A, Suzuki  Y, et  al. Risk factors for complications after 
ileocolonic resection for Crohn’s disease with a major focus on the impact of pre-
operative immunosuppressive and biologic therapy: a retrospective international 
multicentre study. United Eur Gastroenterol J. 2016;4:784–793.
139. Sahami  S, Bartels  SA, D’Hoore  A, et  al. A multicentre evaluation of  risk 
factors for anastomotic leakage after restorative proctocolectomy with ileal 
pouch-anal anastomosis for inflammatory bowel disease. J Crohns Colitis. 
2016;10:773–778.
140. Guo K, Ren J, Li G, et al. Risk factors of surgical site infections in patients with 
Crohn’s disease complicated with gastrointestinal fistula. Int J Colorectal Dis. 
2017;32:635–643.
141. Diederen  K, Sahami  SS, Tabbers  MM, et  al. Outcome after restorative 
proctocolectomy and ileal pouch-anal anastomosis in children and adults. Br J 
Surg. 2017;104:1640–1647.
142. Heimann TM, Swaminathan S, Greenstein AJ, et al. Incidence and factors cor-
relating with incisional hernia following open bowel resection in patients with in-
flammatory bowel disease: a review of 1000 patients. Ann Surg. 2018;267:532–536.
143. Huang W, Tang Y, Nong L, et al. Risk factors for postoperative intra-abdominal 
septic complications after surgery in Crohn’s disease: a meta-analysis of observa-
tional studies. J Crohns Colitis. 2015;9:293–301.
144. Beddy D, Dozois EJ, Pemberton JH. Perioperative complications in inflamma-
tory bowel disease. Inflamm Bowel Dis. 2011;17:1610–1619.
145. Luong TV, Grandt SD, Negoi I, Palubinskas S, El-Hussuna A. Preoperative 
factors associated with prolonged postoperative in-hospital length of stay in pa-
tients with Crohn’s disease undergoing intestinal resection or strictureplasty. Int J 
Colorectal Dis. 2019;34:1925–1931. doi:10.1007/s00384-019-03418-8
D
ow
nloaded from
 https://academ
ic.oup.com
/crohnscolitis360/article-abstract/1/3/otz021/5544997 by Aalborg U
niversity Library user on 05 February 2020
